Literature DB >> 18855572

Targeting RSK: an overview of small molecule inhibitors.

Tam Luong Nguyen1.   

Abstract

Ribosomal S6 kinase (RSK) is a family of serine/threonine kinases that has been identified as a promising anti-cancer target. While a number of protein kinase inhibitors that have potent activity against other serine/threonine kinases were shown to also inactivate RSK, there is keen interest in the three different inhibitor chemotypes that were shown to be RSK specific, since these compounds have tremendous utility as chemical probes in elucidating the biochemistry of the RSK signaling cascade and unraveling the molecular basis of cancer. Because each compound may have therapeutic potential, the nonspecific kinase inhibitors as well as the RSK specific inhibitors will be discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18855572     DOI: 10.2174/187152008785914770

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  24 in total

1.  tPA activates LDL receptor-related protein 1-mediated mitogenic signaling involving the p90RSK and GSK3beta pathway.

Authors:  Ling Lin; Guojun Bu; Wendy M Mars; W Brian Reeves; Sakae Tanaka; Kebin Hu
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

2.  Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFNλ signaling.

Authors:  Barbara Kroczynska; Sonali Joshi; Elizabeth A Eklund; Amit Verma; Sergei V Kotenko; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2010-11-12       Impact factor: 5.157

3.  Survival of HER2-Positive Breast Cancer Cells: Receptor Signaling to Apoptotic Control Centers.

Authors:  Marc Y Fink; Jerry E Chipuk
Journal:  Genes Cancer       Date:  2013-05

4.  RSK promotes prostate cancer progression in bone through ING3, CKAP2, and PTK6-mediated cell survival.

Authors:  Guoyu Yu; Yu-Chen Lee; Chien-Jui Cheng; Chuan-Fen Wu; Jian H Song; Gary E Gallick; Li-Yuan Yu-Lee; Jian Kuang; Sue-Hwa Lin
Journal:  Mol Cancer Res       Date:  2014-09-04       Impact factor: 5.852

5.  The RSK Inhibitor BIX02565 Limits Cardiac Ischemia/Reperfusion Injury.

Authors:  Xi Shi; Margaret M O'Neill; Scott MacDonnell; Paul S Brookes; Chen Yan; Bradford C Berk
Journal:  J Cardiovasc Pharmacol Ther       Date:  2015-06-30       Impact factor: 2.457

6.  RSK2 Binding Models Delineate Key Features for Activity.

Authors:  Rick Gussio; Michael J Currens; Dominic A Scudiero; Jeffrey A Smith; Deborah A Lannigan; Robert H Shoemaker; Dan W Zaharevitz; Tam Luong Nguyen
Journal:  J Chem Pharm Res       Date:  2010

7.  Phosphorylation of eukaryotic translation initiation factor 4B (EIF4B) by open reading frame 45/p90 ribosomal S6 kinase (ORF45/RSK) signaling axis facilitates protein translation during Kaposi sarcoma-associated herpesvirus (KSHV) lytic replication.

Authors:  Ersheng Kuang; Bishi Fu; Qiming Liang; Jinjong Myoung; Fanxiu Zhu
Journal:  J Biol Chem       Date:  2011-10-12       Impact factor: 5.157

8.  Identification of quercitrin as an inhibitor of the p90 S6 ribosomal kinase (RSK): structure of its complex with the N-terminal domain of RSK2 at 1.8 Å resolution.

Authors:  Urszula Derewenda; Mykhaylo Artamonov; Gabriela Szukalska; Darkhan Utepbergenov; Natalya Olekhnovich; Hardik I Parikh; Glen E Kellogg; Avril V Somlyo; Zygmunt S Derewenda
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-01-19

9.  Integrins promote cytokinesis through the RSK signaling axis.

Authors:  Shomita S Mathew; Bethsaida Nieves; Sharon Sequeira; Savitha Sambandamoorthy; Kevin Pumiglia; Melinda Larsen; Susan E Laflamme
Journal:  J Cell Sci       Date:  2013-11-27       Impact factor: 5.285

10.  RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.

Authors:  Violeta Serra; Pieter J A Eichhorn; Celina García-García; Yasir H Ibrahim; Ludmila Prudkin; Gertrudis Sánchez; Olga Rodríguez; Pilar Antón; Josep-Lluís Parra; Sara Marlow; Maurizio Scaltriti; José Pérez-Garcia; Aleix Prat; Joaquín Arribas; William C Hahn; So Young Kim; José Baselga
Journal:  J Clin Invest       Date:  2013-05-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.